Skip to main content
 
Print Page    E-mail Page    RSS    E-mail Alerts    Tearsheet 

Event Details

Seres Therapeutics Announces Interim Results from SER-109 Phase 2 ECOSPOR Study in Multiply Recurrent Clostridium difficile Infection Corporate Conference Call

Friday, July 29, 2016 8:30 a.m. ET  

Webcast Presentation

Title
Seres Therapeutics Announces Interim Results from SER-109 Phase 2 ECOSPOR Study in Multiply Recurrent Clostridium difficile Infection Corporate Conference Call
Date / Time
07/29/16 8:30 a.m. ET